Posters

A real-life evaluation of the effect of direct-acting antivirals in hemodialysis patients with chronic hepatitis C

Volume 30 · Issue Supplement 1 Publish Date: July 25, 2019
Nurten Nur Aydın Firdevs Aksoy Ilknur Yavuz Serap Iskender Arzu Altuncekic Yildirim Ilknur Esen Yıldız Iftihar Koksal
Full Text PDF
DOI

Published In

Turkish Journal of Gastroenterology

Volume 30 · Issue Supplement 1

Pages: 39-40

History

Published Online: July 25, 2019

Copyright © 2019 Nurten Nur Aydın, Firdevs Aksoy, Ilknur Yavuz, Serap Iskender, Arzu Altuncekic Yildirim, Ilknur Esen Yıldız, Iftihar Koksal

Nurten Nur Aydın
Department of Infectious Diseases Karadeniz Technical University Faculty of Medicine
Firdevs Aksoy
Department of Infectious Diseases Karadeniz Technical University Faculty of Medicine
Ilknur Yavuz
Department of Infectious Diseases Giresun University Faculty of Medicine
Serap Iskender
Department of Infectious Diseases Kanuni Education Hospital
Arzu Altuncekic Yildirim
Department of Infectious Diseases Ordu University Faculty of Medicine
Ilknur Esen Yıldız
Department of Infectious Diseases Rize University Faculty of Medicine
Iftihar Koksal
Department of Infectious Diseases Karadeniz Technical University Faculty of Medicine
Aydın, N. N., Aksoy, F., Yavuz, I., Iskender, S., Altuncekic Yildirim, A., Esen Yıldız, I., & Koksal, I. (2019). A real-life evaluation of the effect of direct-acting antivirals in hemodialysis patients with chronic hepatitis C. Turkish Journal of Gastroenterology, 30(Supplement 1), 39–40. https://doi.org/10.5152/tjg.2019.25
Endnote/Zotero/Mendeley (RIS) BibTeX
Full Text PDF

Abstract

INTRODUCTION: Hepatitis C virus (HCV) infection is widespread in hemodialysis patients worldwide. Successful results are achieved in the treatment of HCV with effective, well tolerable direct-acting antivirals (DAAs). However, studies of the effectiveness of new generation DAAs in the treatment of HCV infection in hemodialysis patients are limited. We investigated the effectiveness of DAAs in hemodialysis patients with HCV infection. METHODS: Twenty-three HCV positive treatment naïve or experienced (IFN/pegIFN ±RBV) hemodialysis patients were enrolled between 2016 June-2018 May. Three patients were excluded for not attending follow-ups regularly, and the data for 20 patients were included. Patients’ demographic, virological, and genotypic characteristics, liver fibrosis status, DAAs started, and sustained virological responses at the 12th week (SVR12) were recorded. DAA regimens based on the treatments patients were using and potential drug interactions. Patients completing treatment were followed for 12 weeks for SVR. RESULTS: The mean age of the patients was 57.8 (±10.5). Ninety percent were men; 55% were treatment–experienced and 45% were treatment-naïve. Ninety percent were non-cirrhotic and 10% had compensated cirrhosis. Of the treatment-experienced patients, 45.5% were nonresponder and 54.5% were relapsed (Table). Eighteen patients with Genotype 1b were treated with paritepravir-ritonavir-ombitasvir-dasabuvir (ProD) for 12 weeks, one patient with Genotype 4 received ProD+ribavirin for 12 weeks, and one patient with Genotype 2 received sofosbuvir+ribavirin for 24 weeks. HCA RNA was negative on the 4th week in 85% of patients, and was negative in all patients on the 12th week, apart from the patient receiving the sofosbuvir+ribavirin regimen. At the end of treatment, HVC RNA was negative in all patients, and the SVR12 rate was 100%. Patients’ treatment responses were independent of previous treatments, liver fibrosis status, and hemodialysis duration. No marked side effects or complications were observed, apart from sleeplessness in one patient (Table).  CONCLUSION: Our study data confirm that new generation DAAs in hemodialysis patients provide high SVR and are well tolerated, as in patients other than those with chronic kidney disease. Achieving cure in hemodialysis patients is important in terms of preventing cross-contamination and of global elimination of HCV.

Most read articles by the same author(s)

Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 30 · Issue Supplement 1
Pages 39-40
DOI 10.5152/tjg.2019.25
History
Published Online July 25, 2019
Copyright
Copyright (c) 2019 Nurten Nur Aydın, Firdevs Aksoy, Ilknur Yavuz, Serap Iskender, Arzu Altuncekic Yildirim, Ilknur Esen Yıldız, Iftihar Koksal
Affiliations
Nurten Nur Aydın
Department of Infectious Diseases Karadeniz Technical University Faculty of Medicine
Firdevs Aksoy
Department of Infectious Diseases Karadeniz Technical University Faculty of Medicine
Ilknur Yavuz
Department of Infectious Diseases Giresun University Faculty of Medicine
Serap Iskender
Department of Infectious Diseases Kanuni Education Hospital
Arzu Altuncekic Yildirim
Department of Infectious Diseases Ordu University Faculty of Medicine
Ilknur Esen Yıldız
Department of Infectious Diseases Rize University Faculty of Medicine
Iftihar Koksal
Department of Infectious Diseases Karadeniz Technical University Faculty of Medicine
Cite this Article
Aydın, N. N., Aksoy, F., Yavuz, I., Iskender, S., Altuncekic Yildirim, A., Esen Yıldız, I., & Koksal, I. (2019). A real-life evaluation of the effect of direct-acting antivirals in hemodialysis patients with chronic hepatitis C. Turkish Journal of Gastroenterology, 30(Supplement 1), 39–40. https://doi.org/10.5152/tjg.2019.25
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Outlines